Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)